STENTYS Adds Branch Office in Dubai

PRINCETON, N.J. and PARIS – September 25, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world’s first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announces the creation of a branch office in Dubai (United Arab Emirates). This new entity supports the distribution network deployed in the Middle East since 2013, which today includes Saudi Arabia, Kuwait, the United Arab Emirates, Jordan, Lebanon, Tunisia and Egypt.

The STENTYS employees who will support the distributors in these various countries will also be responsible for training cardiologists, notably in anticipation of next year’s launch of the Sirolimus-eluting stent and its new delivery system.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, explains: “Establishing this office in Dubai is a tangible illustration of our strategic focus on global commercial development, especially in the fast-growing Middle East stent market where the demand for our Self-Apposing stent has been increasingly strong.”

About STENTYS

STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS’s Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low one year mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents.

More information is available at www.stentys.com.

This press release contains forward looking statements about the Company’s business. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company’s products, market acceptance of the Company’s products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 “Risk Factors” of the Company’s 2011 Registration Document (document de référence) filed with the Autorité des Marchés Financiers in France on August 27, 2013 under number R.13-040 as such section may be updated from time to time.